Two Big Tech Moves That Caught Our Eye This Week, and Gilead Gets on the GLP-1 Train 6/14/24

14 Jun 2024 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money" Episode - Two Big Tech Moves That Caught Our Eye This Week, and Gilead Gets on the GLP-1 Train (6/14/24)

Episode Overview In this episode of "Fast Money," hosted by Melissa Lee and a panel of expert traders, the discussion revolves around significant movements in the tech industry, especially focusing on Apple and Netflix, and Gilead's potential entry into the obesity drug market. Key topics also include stock performance, market trends, and competitive landscapes.

Key Highlights

Big Tech's Performance

  • Apple and Netflix Surge:
  • Apple shares rose nearly 8% following the WWDC, hitting new records and briefly reclaiming status as the world's largest company.
  • Netflix is trading close to its record high from November 2021.
  • Analysts suggest these stocks could influence market dynamics positively.
  • Market Dynamics:
  • Tim Seymour emphasized the leadership roles of Apple and NVIDIA in pushing the Nasdaq to new highs.
  • Discussions highlighted the contrasting performance of defensive stocks, like regional banks and homebuilders, which did not respond favorably despite decreasing interest rates.

Gilead's New Drug

  • Obesity Pill Development:
  • Gilead's stock received a boost thanks to early results from its experimental obesity drug, showing promise comparable to drugs by competitors like Eli Lilly and Novo Nordisk.
  • The panel discussed potential implications for Gilead in the GLP-1 drug market, despite noting the study's limitation to monkey subjects, raising questions about human application.

Sector Analysis

  • Transports and Consumer Goods:
  • The DJT (Dow Jones Transportation Average) dropped to its lowest level since November, hinting at vulnerabilities in the transport sector.
  • Target's poor performance, contrasting with Walmart's growth, sparked debate over consumer spending trends and inflation's impact.

Investment Strategies

  • Apple Trading Outlook:
  • Panelists proposed that the upcoming iPhone refresh cycle could drive further consumer interest and sales momentum.
  • Concerns were raised about Apple's valuation, trading at high multiples with limited growth prospects, and how this could affect future performance.
  • Walmart vs. Target Discussion:
  • Walmart was favored over Target due to its robust grocery segment and adaptability in current market conditions.
  • Target's struggles in maintaining market share and managing inflationary pressures were highlighted.

Insights on GLP-1 Drugs

  • Competition and Market Opportunity:
  • The discussion underscored the fierce competition in the GLP-1 drug market, highlighting the need for companies to innovate and differentiate themselves.
  • Panelists noted that while current innovations show promise, they remain cautious about the sustainability of Gilead's potential breakthroughs.

Key Takeaways

  • Tech Dominance:
  • Apple and Netflix are leaders in stock performance, suggesting continued investor interest in tech amidst broader economic concerns.
  • Consumer Behavior Trends:
  • Inflation impacts consumer preferences, influencing company performance in discretionary sectors.
  • Pharmaceutical Innovations:
  • Gilead's entry into the GLP-1 market may alter competitive dynamics, but cautious optimism remains due to the early-stage nature of its developments.
  • Market Strategy:
  • Investors are urged to weigh the potential for growth against high valuations, particularly in tech stocks like Apple.

Conclusion The episode encapsulates a critical analysis of current market trends, emphasizing the significance of tech stocks in shaping investor sentiment and economic forecasts. The discussions about Gilead's new obesity drug highlight the ongoing evolution of the pharmaceutical landscape, underscoring the intersection of innovation and market dynamics.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:01Live from the Nanzac Market Site in the heart of New York City's Times Square. This is Fast Money. Here's what's on tap tonight. Big tech's big week. The XLK ETF soaring to all-time highs today with a couple of notable names leading the charge. What to make of the run in these stocks and how you should trade them. And gilding the lily. Long-struggling Gilead getting a boost on some positive results. Of course, potential oral obesity drug. What we know now and what it could mean for the GLP-1 space. Plus, transports truck lower as the DJT hits its worst level since November. Boeing faces more turbulence on production delays in another congressional probe.

0:36And Target missing the mark, falling further behind its top competitor. I'm Melissa Lee. Coming to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Courtney Garcia, Steve Grasso, and Guy Adami. We start off with two big tech moves that caught our eye this week. Apple jumping nearly 8 % since its WWDC kickoff on Monday, hitting brand new records. And briefly reclaiming the spot as the biggest company in the world. Meantime, Netflix putting in its own winning week, closing within 5 % of its record high, hit way back in November 2021. So what do these two moves tell us about the markets we have right now?

1:10Should you be in these trades? Tim Seymour, what do you say? I think you should. And I think that the Apple trade is one that looks like a trade now. And, hey, why weren't we assuming Apple was going to break out two weeks ago? Because nothing at WWDC ultimately, and we're going to get into that. But back to the importance of Apple to the market is the fact is that the Nasdaq over the last two days has set new relative highs to the S &P, all time highs, all time relative highs. That leadership in the form of both Apple and NVIDIA, I think, is something that can continue. And I think that, you know, the Netflix dynamic here is also a case where you've got clear leaders that even through the other part of the week that is notable, it's a week where we digested a Fed that acknowledged and a labor market that's certainly coming in as we need it to, an economy that's probably not falling apart, but it's showing some signs.

1:59These are all names that are going to be defensive in that kind of an environment. And Netflix, you know, we talk at nauseam as we should how far ahead they are the rest of the competition. The names that should have responded better to what the Fed gave us the other day did not do well for the week in particular. And I thought that was sort of interesting. You want to be defensive? Sure. But how about regionals? How about homebuilders? Those didn't do particularly well. Yeah, which we've discussed. The region of the KRE, I mean, throw a chart up, is not traded particularly well today again. And that's with rates going down.

2:30And I think the market is finally, I think, starting to catch wind of some of the commercial real estate issues that are out there. And I think it's manifesting itself in the KRE. And you're right about the homebuilders as well. So two areas that theoretically should have gotten a boost with rates going down have not participated. And we'll talk about the transports, which its own animal. But those things, I think, have to give you a little bit of concern. Maybe it's too late for regionals to actually perform because you're still worried about commercial real estate. So it could be too little too late.

2:58And remember, when they cut, there's going to be a long and variable lag too. So maybe that's not going to be enough to bail out at least the regional banks. As far as Apple, I think the refresh cycle is going to be huge. I think it's going to pull in people like myself, older people that want to have AI. How old are you, Steve? 70. Okay. You don't look a day over 69. I feel like I look good for 70. It's interesting how you presented that. Yeah. So that's going to cause you to buy the 15 Pro as opposed to a 14 or a 15 regular? Yeah, I think that's going to spoil you. The curiosity about what Siri can do for you?

3:34Siri is terrible. But I think there's a host of other things with emails and things that can make your life a little bit more easy for the mundane tasks. But I wouldn't have done that if there wasn't this upgrade cycle or this refresh cycle. I would have waited for another one. People usually upgrade for a camera. Now they're upgrading for AI. And I think that, and I said this last time, I think Apple just had to do enough to not shoot themselves in the foot. And I think they did enough. It is healthy if it retraces a little bit and comes back. But when you're dealing with that next iteration of the iPhone in September, you're probably eating up some time here.

4:14So you'd have to see the overall market sell off before you get the opportunity. Yeah, and I do agree with that. I think the refresh cycle with the iPhone is clearly this is the thing they needed to kickstart that after they had sales declines five in the last six quarters. And they needed something like this. And especially when you get this kind of upgrade, that does tend to bring some more customers from a Samsung to an Apple. And I think what it's doing to the markets is pretty fascinating, where we've always been talking about the Magnificent Seven and all these companies have been doing very well.

4:38You now have three companies, whether it's Apple, NVIDIA, Microsoft, now over 20 % of the S &P 500, just showing how much this AI story is important to the investors right now. And I do think it is that much more important. It probably will continue. I think you're right. I think these are likely going to be the leaders in the short term. I think longer term, there's still plenty of opportunities you want to make sure you're invested in also. But that kind of FOMO trade, people are wanting to get in here. the more and more it's going up. But I don't think that's ending in the short term. So in every market environment, we want to be in these names.

5:07Right? I mean, that's what it seems like. No matter what the market scenario, Guy, we want to be in those names. You want to be defensive. You want to be offensive. You want to be in these names. Outside, well, I mean, I know where you're going with this. And the answer is yes, only because of the way they traded. By the way, she's trying to paint you into a corner. I'm not. Be careful, Guy. I have no brush. Will Robinson, danger. I have no brush. Yeah. You're uncomfortable. I'm very aware, which is why I'm trying to parse some words. But, no, I totally get it. Listen, outside of that three-month period where Apple was a disaster and the broader market went higher, you're right.

5:38Seemingly, in every environment, there are a handful of names that do well. Why? Because when the broader market sells off, they become defensive. They become some sort of perceived flight to quality. And when the market's doing well, they're bolstered by that. I think I saw yesterday, NVIDIA is now over 400 ETFs, of which is one of the top 15 holdings. I mean, that's a staggering thing if you think about it. So money flows suggest you are correct. However, by definition, there has to be some sort of scenario where those stocks don't. Sorry, got it. Well, the scenario might, in fact, be that that there's a more competitive landscape in AI.

6:11And, you know, Samsung is going to argue that we've been closer to to where Apple's even articulating they want to get tomorrow for a long time. I the reasons why I feel better about Apple are partly based on how much underperformance there was. I mean, Apple took two years to break to fresh new highs. Now, that means it obviously reflected fundamentals and a lagging and even a falling revenue base in iPhone innovation that was lacking. But it massively has underperformed for a long time. This move, by the way, technical. I'm not a technical geek, and they're nice guys. They're not geeks. There's a lot of people that come on the show, and they're gals, too.

6:47But this is a flagpole formation, if I ever saw one. And you have a breakout. And this is something that I actually think is very important from long term resistance at 195. So this is to me a stock that's got fresh legs. This is a stock that the valuation is the toughest part of this story. But this refresh cycle is something that, you know, I think has legs because there was a time we felt like people are just like cars. They're better made. They're driving them longer. But this gives people a reason to actually get out there and refresh the phone. And that iPhone 15 right now has reason to say, hey, we're at least in the AI game, which gets people at least on board.

7:23Why wouldn't it be safety? They have tremendous balance sheets. They're profitable companies. The Russell is not profitable. Right. So 50 percent of the Russell 2000 is not as unprofitable companies. So you need a better economy, lower rates for them to be profitable. So when you look at the overall and markets go up on average, historically, 10 percent every year since the inception of markets. And now where tech is overlaid in every 11 of the sectors that we have right now, tech will improve and those other sectors will buy the technology that these companies are offering. They'll only become more profitable and it'll make the whole market more efficient.

8:03So when you look at where you're funneling in, now I'm not saying the market cannot sell off. I think the market can sell off and will sell off as it does. But those sell offs are shorter in duration than they've ever been before. We have a market and fast forward. I guess I guess the question for me is when will we get to a period or what market scenario will it be for them to relatively underperform some of the areas in the market that haven't had as many gains? The value oriented sort of sectors like the banks, maybe. And I think at some point in time, you're going to have investors shift their focus to the fact that it needs to improve the bottom line.

8:39So I think how it improves Apple is the fact people actually have to buy the phones, right? So they are going to have additional revenue sources, whereas you have a lot of companies right now who are just investing billions of dollars into artificial intelligence with no additional or very incremental into their revenue. And at this point in time, people are willing to pay up for that. But I do think you get to a point that if you're not actually showing it in your bottom line, people are going to start to reflect that on the stock prices. So I don't know if we're there yet, but yes, I think at a certain valuation, you will get there.

9:04And I think that is a concern. I think it's interesting that the psychology behind upgrading for the individual seems to be different from the psychology for corporations. I mean, if you believe that this is going to spur some huge upgrade cycle or even small upgrade cycle for Apple, but you are skeptical that corporations will upgrade to the Microsoft laptop with the AI key, why is there that difference? I'm not a big believer in it. I think the upgrade cycle was always there. I think it was going to, you know, maybe this is on the margins. But not, you know, I don't think it's going to be that incrementally.

9:36That's just me. And look, do valuations matter? I think so. Now Apple, all it's done this week has gotten more expensive. It trades now 30 times next year. It has maybe 9 % EPS growth. I don't know, maybe 8 % revenue growth margins that have been flatlining now for the last couple of years. I mean, that's not great. Now, I understand the premium multiple might come on the fact of services, which continues to trend the right way in terms of the overall percentage of revenue. However, it's an expensive stock. I just that 75 percent gross margin on software and services is not to be overlooked. And on the base case, you're somewhere around, you know, eight, nine percent growth.

10:13But conceivably, this really is about a software dynamic. This really is about upgrade. This really is about extracting extra services out of the consumer. But the other thing that makes Apple incredibly defensive in all markets is the fact that, I mean, didn't that monstrous buyback and signal tell you that Apple is an all-weather stock? That they've also made it very clear they don't see any reason to hold a lot of cash. They're going to be 100 % cash neutral. That, to me, for a company that generates cash. Remember what we were most concerned about with Meta before they went into the year of efficiency was that, you know, if they had just said we want to be an ATM because we've got this installed base.

10:50Actually, that's Apple. Excuse me. We've got we've got the subscriber base around the world. That's four billion. We've got this percent of the world's population. All people wanted to hear is just do your core business and give money back to consumers. And Meta would have rallied well before the massive rally it's had. It took the year of efficiency to remind people that they could be efficient and give capital back. I love the fact that I know Apple is going to do the right thing from a capital markets perspective. It has for the last 10 years once they started this cash pile. All right. Well, our next guest used to be the biggest bear on the street, but this week's WWDC prompted him to upgrade the stock to a neutral.

11:24Let's bring Light Shed's Walter Pysik. He's a partner and TMT analyst at the firm. Walter, great to have you with us. You're not a huge believer, though, that there's going to be a massive upgrade cycle. So why the pivot from sell to neutral? You know, I think I'm just trying to get away or get out of the way of this massive AI train that's just waffling people all over the place. It was predictable, I think, after they reported earnings that the stock was going to run up into WWDC. I just assumed it would sell off. So when that thing moved through 200, what it was telling me is what a lot of your panelists have talked about, is this belief that, yes, the upgrade cycle is going to happen.

12:03And I don't have any data points to disprove that in the near term. We'll come back when we do get the data points, when we hear from the operators about what exactly is happening. But in the meantime, the bulls have won the day in terms of getting people hyped up that there's going to be 10 % or 15 % growth and there's going to be this massive upgrade cycle. But we've heard this before. I mean, years ago, it was the metaverse that was going to drive the super cycle. Last year, the super cycle was going to kick in for whatever the reason was, and it didn't. The upgrade rates kept going lower. Obviously, AI is new, but Samsung had a lot of AI features.

12:37Did their upgrade cycle improve last year because of AI specifically? No, it didn't. It went down with Apple and the rest of them. Apple's in a very easy point right now because people have very old phones. And there's a variety of reasons why you're going to upgrade your phone. So you should see some stabilization and inversion. But to expect operators to come in and subsidize that, probably not going to happen. And if there are some glitches in some of the early, I mean, we've had the, I've been trying this beta of the iOS 18. They still don't have the serious stuff in there. If you start getting reports that it's not delivering anything that gets you that excited to upgrade the phone, maybe you don't get a big enough upgrade cycle to deliver on these super bullish now growth estimates of 10 % and 15 % that are not reflected in consensus.

13:28Consensus didn't move after WWDC. What it moved on is really the bulls pushing this thesis that we're going to 10 % to 15 % top line growth within the next year or two. So we'll revisit it in a couple of months and see if there's any evidence that that's true. But, you know, people upgrade for different reasons. And I didn't see anything from no one came out of WWDC saying, wow, I need to get the phone for that reason. And everyone's saying it was as expected. All of these things were predicted. So what exactly has everyone so convinced that we're going to see this massive upgrade cycle and 10, 15 percent growth?

14:06Which of the services that they announced? Walter, I've been the victim of the steamroller in a bunch of different names. So let me ask you this. In terms of services revenue, Tim just mentioned the margins. If they can trend up to, let's say, 28, 29 percent, does that change the narrative a little bit in terms of the valuation at this point, which I still think is stretched? Absolutely. But again, what is the bull thesis now? It's the iPhone growth. That's equipment revenue. That's not the high service stuff. So we keep switching what the narrative is, right? A couple of years ago, it was like, oh, it's going to be a services company.

14:41So let's put a high multiple on it. And then a lot of the services companies that were out there, their valuations imploded and you were getting a higher multiple for owning an equipment company. Now we're saying the revenue is going to come from equipment, but at the same time, and we're pitching this as a service company, like that doesn't fit. Doesn't it come, Walter? I mean, I'm sorry to interrupt you, but doesn't it come? Once people have more of these AI-capable phones, I mean, it was a developers conference because there are going to be apps developed based on AI, and so there will be more services revenue, you know?

15:11I mean, doesn't it go hand in hand? I mean, one of the theories for that service revenue, which is two to three years from now, is that it's Apple themselves charging you extra for Apple services, which they don't typically do. And one of the other pitches that I've heard many times in the past couple days is, well, Apple, they can provide you 20 % of the population. But the AI only works on the most recent phones. So even if half the phones, 70 % of the phones, let's say all of the phones get upgraded to an AI-capable phone over the next year, it's still only 15 % of the base that you can actually layer these AI services on.

15:53So, if you're going to build service revenue on top of this install base, the install base of AI-capable phones is only going to be 10 % or 15 % of that billion-five iPhone base that's out there. So, it's going to take a couple of years to get the install base up to a point where you can sell services. And then the question is, where is that service revenue coming from? Is Apple charging you for, do they charge you for iMessage? Are they charging you for satellite messaging? Are they charging you or are you just hoping to get enough app downloads where ChatGPT is going to charge you 20 bucks, right?

16:28And basically, Apple's going to take their VIG, assuming that the regulators don't stop them from taking the VIG that they're getting today. Walter, good points there. Thank you. Walter Pysik of LightShed. How about that argument? Well, it's going to be a small percentage, right? 15 percent. I respect how Walter's gone from being a bear to just being neutral. And he's saying, let's wait and see. I think that's the right thing to do. I also, in reading his notes, I was, his interpretation is something, it's not how I thought about it. We just started talking about this refresh cycle. He says what this will do, it will stabilize or there'll be an inversion of the lengthening of the refresh cycle.

17:08So that's interesting because, again, much back to the car analogy, we know cars are on the road seven, eight years. And by historical standards, you need to people need to buy new cars, except for when the cars are made to run up to 150 ,000 miles now. So I think that's fascinating because I do think people are not seeing that. And I think that's an important point, that nuance that he said. I think it's actually going to shorten the cycle. And I use the analogy of the camera before where they were having a new camera every time, every time they refreshed it, that camera got better. And I think AI, we're just in its infancy in AI, and I think AI is going to get dramatically, exponentially better with every iteration in shorter spans.

17:48All right. Coming up, missing the target. The retailer already down 10 percent this month as its biggest rival continues to make big gains. Can this stock catch up with the competition? That's next. Plus, more bad news for Boeing. Senator Chuck Grassley launching a new probe into the embattled plane maker inside the company's latest headache next. This is Fast Money with Melissa Lee right here on CNBC.

18:22Welcome back to Fast Money. We've got a buzzkill on target. Shares slipping nearly 3 % today and posting their lowest close since January. Shares are down over 11 % in just the past month. Meanwhile, rival Walmart is up by almost the same amount in that time. seems like a good opportunity to play America's favorite game. Which one is that? It's not Trader or Faded. But this is America's other favorite game. Would you rather? There's so many. Would you rather? Oof. Would you rather? Courtney, would you rather Target or Walmart? I would take Walmart mainly because Target is such a high exposure to your discretionary goods.

18:56It's like over 50 % of their sales. And I do think we are in this environment right now where inflation is really hurting a lot of consumers right now. And they're continuing to have to decide where to shop. So Walmart is actually benefiting. They're having higher income consumers trade down into Walmart and actually buying more groceries there, whereas Target is actually losing customers on discretionary purposes. So I would go to Walmart for that reason. Not only would I rather, but I did. I bought more Walmart this week. And I just as much as I think Target's interesting here. And after a 30 percent underperformance year to date to Walmart.

19:27And boy, you could have a fun time trading this pair because you've had a lot of volatility between these two. But we spent time on this desk that, you know, the week before earnings, when Target pointed out that they were doing some some promotion and they were being aggressive on pricing, you said, hey, they're playing offense. This is actually really exciting. They wouldn't be doing this and they wouldn't be coming out and doing this if they had bad news to announce on earnings. And boom, there they did. I think there's something also to be said about slowly. The macro is something you need to watch more for Target than Walmart.

19:56Walmart, as we know, is attracting a higher income consumer. What we read even in the University of Michigan Consumer Competence today, which was at seven month lows, is that middle income is having some trouble. It's not a big surprise. It's unfortunate. But that's in line with the labor market. So I think you stay with Walmart. There is a negative Reuters article on Target today highlighting what they've lost in terms of market share. They've lost market share in household goods, in furnishings, in clothing, in electronics, basically every single category. The average purchase price has gone down as well.

20:28But there's valuation issues here. I mean, in terms of the choice. Valuation issues in terms of one would think Target is compelling on valuation, which I get. And that's been the argument forever. But, you know, Joker, Joker, and the Triple, remember the Joker as well? Jack, what's his name? I don't remember, actually. I'm sure somebody will get in my ear and tell me. But, no, I'm Target as well. Listen, Goldman Sachs on the 3rd of June took them off the conviction buy list. Stock was$156 that day. It's$141 today. People will talk about this on valuation. The problem is it's going to continue to be a value trap, I think, because they're in the wrong product mix.

21:02And outside of that little spike we saw when they got inventories back in control, I mean, this has just been a really tough hold. But if inflation abates and the consumer is still employed and the Fed is done raising rates and the Fed is going to cut, isn't that the time for the target customer to maybe go back, for target to maybe gain some more share? Or the other ones are going to even outperform even more because Walmart has a healthy amount of groceries, a lot more groceries. I think it's like 50 percent of their of the revenue is derived from groceries. But you said it. The only thing maybe you didn't say this part.

21:36The only thing that they actually gained share in or improved on sales was beauty. So all of the other segments were down. So Walmart, I own it. I will continue to own it. I don't want to touch targeted. Actually, on a technical level, it broke the 200 day moving average. where last month it sort of tested it and then bounced and rallied, and now it actually broke. Jack Barry was the host of Joker's Wall-Fi. Did you let it out? You said triple, triple. You're the only one. Joker and a triple. Joker, she said Target. No, she didn't. She said Walmart. I said Walmart, too. Everybody here at the CESC is Walmart.

22:11Yes, we're all Walmart. All chose Walmart, which may be the ultimate contrarian indicator. All right, there's a lot more fast money to come. Here's what's coming up next. Another Boeing bummer. The aerospace giant facing the pain of a brand new congressional probe that threatens to keep the stock grounded even longer inside the company's latest headache. Next. Plus, a new contender joins the GLP-1 Battle Royale. Gilead says their weight loss pill is the real deal. But should you believe the hype? We've got the skinny on this obesity offering. You're watching Fast Money, live from the NASDAQ market site in Times Square.

22:48We're back right after this.

Read the full transcript

22:55Welcome back to Fast Money. More headwinds for Boeing sending shares another 2 % lower today. Reuters reporting the planemakers warning suppliers it is slowing at 737 targets by three months, saying it now expects to output 42 jets a month by September rather than in June. And that's not all. Republican Senator Chuck Grassley is also launching a fresh congressional probe into the FAA and Boeing, tied to the midair blowout in January. The NTSB is getting involved in an incident on a Southwest flight last month where a 737 MAX went into a Dutch role. The New York Times reporting the FAA is investigating the authenticity of titanium in Boeing planes and some Airbus jets.

23:34It's a lot. It's a lot going on. Not getting any better. I know you guys win said Dutch role. No, I mean... Apparently it's when the tail moves in a certain way and it's very unusual for it to happen. It's not a pastry. It sounds like a pastry to me. It sounds like a few things. Anyway. Probably. Boeing shareholder. Yeah. Aren't you sick of this? Yes. But I think the numbers as it related to slower delivery count, we just got delivers. We heard, I don't know, 28 in May, down from 50 a year ago. The run rate on max needs to be about 38. It's disappointing. It's slowing down free cash flow. The regulatory headwinds are tough.

24:09And any headline, I don't know any of the details on what you've just announced with that flight that is just being brought to brought to light in terms of what went on there. But the story for for Boeing on paper is is about free cash flow and it's about earning power and it's about a business that also is heavy duty defense. And it's it doesn't mean the stock's going to get up and going anytime soon. There's a lot of people that have fatigue here. I'm one of them, but I'm not running here. I mean, as nefarious as a Dutch roll sounds, I mean, sounds a little. It sounds like a pastry with maybe some jelly in it.

24:46Oh, yes. Well, noted. Probably sounds a lot worse when you're on the plane. In the context of A &E, there's something completely different. But Steve has said this, and he's right. He's going to wind up being right. I mean, this stock would probably be a lot lower, but for the fact that they're in this duopoly. I still think at some point the market has some epiphany and say, wait a second, there's this whole defense business that we're not valuing at all, and the stock finds its legs. But that's been the wrong argument for a while. I think it's perception reality and people perceive this company to be troubled, troubled.

25:17And it actually is troubled. But we have to figure out what they are going to do. There's a lot of plans and nothing seems to be getting better for them. So everything that they do gets worse and every incident that they have exacerbates it. So you can't buy the stock until something clears up. It's exhausting. Every time you think they're getting to an end of it, there's another report. Like the fact that this just came out and a lot of these happened a few months ago, I think is actually a little surprising, like how social media didn't like spur this up in the first place. Things a little surprising.

25:46There's always seems to be another story with them. So, I mean, long term, they are a duopoly. I do think eventually they are going to continue to have airplanes that are ordered from them. Short term, I think there's just too many issues here to go into when there's so many other areas of the market that are really good opportunities. That's not that I necessarily think it's an issue long run. But, you know, why jump into this when there's plenty of areas that have way better opportunities in the short term? Coming up yet another competitor is entering the GLP-1 space. Gilead getting into the game with an oral drug.

26:14But should you believe the hype? We'll debate that next. Plus Bernstein getting bullish on Bitcoin calling for massive gains in proxy play micro strategy. The numbers behind this blockbuster call next. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

26:39Welcome back to Fast Money Stocks. Finishing mix and the week, the Dow closing out its fourth straight down day, its longest losing streak since mid-April. The S &P falling slightly for the first time this week, and the Nasdaq just barely holding on for another record close. It's fifth in a row. Meantime, cruise stocks sinking after Bank of America know the space is facing pricing pressure. Norwegian, Carnival, Viking, Royal Caribbean all dropping sharply today. And Adobe surging after yesterday's earnings report, the best performer on both the S &P and Nasdaq today. Finally, Broadcom jumping more than 3 % to end its best week ever.

27:11The chip stock up over 23 % since Monday. Wow. And just in the past hour, Vermont Senator Bernie Sanders issuing a press release announcing that Novo Nordisk CEO will voluntarily testify before a Senate committee focused on the cost of GLP-1 drugs Ozempic and Wegovi. The date of the hearing not specified in this release, but of course this is an issue that Senator Sanders has been pursuing vehemently. All right. Well, Gilead gaining today, topping the tape up three and a half percent. The pharma company putting out preclinical test results on his oral GLP-1 drug ahead of next week's American Diabetes Association meeting.

27:48The data showing participants losing an average of six and a half percent of their body weight over 36 days in line with results from Eli Lilly's oral GLP in trial. But one potential snag, Gilead's study was conducted in monkeys, not humans. So the participants were monkeys. It's not known whether those monkeys had diabetes either. You laugh at that, but, I mean, it's important to know some of these, you know, differences. Bananas are high in sugar. Potassium. Anyway, but you're noting today on the call, Tim, that Gilead has just been kind of a dog. It's been more than a dog. And I know our clever team, when they write some of the intro copy, they said, you know, the term was gilding the lily, which means you're basically taking something that's already beautiful and you're putting gold on it, which is like great.

28:38This has not been golden or lily like. And in fact, it's down 20 percent ish. It's a company that I think really has zero patronage on the street. And you can make an argument. That's a great setup for a company who is and has invested in oral GLPs and is in the game. Is is you know, this is an opportunity here. But again, the pipeline there looks very barren. And the issue is that this is a company that really for a long time between hepatitis and HIV had the important franchises. And those are things that have been slowly eroding. That's the whole story in pharma. I think it's interesting here at these levels.

29:14I think on valuation, even with the pipeline they have, I think it's been discounted. Today's stock move shows that. It's made a two year low earlier this week. So it's been awful to Tim's point. But Jeffries made and Jeffries is very good in the space. They put an$80 price target. They talked about some of the concerns that you just brought up. But, I mean, the stock, if they can get anything right just on the margins, I mean, this stock should be significantly higher. When I say significantly higher, like$80 is not a stretch here. All right. Meantime, biotech companies raising$6.8 billion in venture capital funding in the first quarter.

29:45According to BioPharma Dive, that's almost a billion dollars more than the most active quarter of 2023. And one VC firm is helping early stage companies in the field get from seed stage to the next big funding round faster. Portal Innovations partners with companies in emerging biotech hubs, connecting them with funds, lab space and key industry partners. Joining us now is John Flavin, the founder and CEO of Portal Innovations. John, great to have you with us. Thanks, Melissa. Great to join. We're just talking. We probably talk every night about GLP-1 drugs in the pipeline. GLP-1 drugs are out in market right now.

30:19How much of the auction is being consumed in the venture space in terms of capital by the weight loss category? And how do you think about it since we do have such huge companies with huge market share right now already in the space? Well, it's a very exciting space. Obviously, you know, first generation GLP-1 drugs, you know, advanced by Lilian Novo has been quite transformative and a breakthrough for many cardiometabolic diseases. naturally the eyes turn to the pipeline, not only the competitive landscape, but how do these companies improve either the dosing profile or in the case of GLP-1 drugs, some of the untoward side effects that are experienced, such as muscle loss.

31:04And so there's a whole wave of new technologies, companies, and venture investments that are made at the front end of the process to get a pipeline in place. Many of these reside oftentimes beginning in a university. We've invested in a company called Sintus. It's fun out of Bob Langer's lab. He's a co-founder of Moderna and out of MIT. And it's a company called Sintus that's working on an alternative that's a polymer that is delivered by pill to the small intestine to be able to add to the armamentarium of obesity drugs that aren't acting necessarily the same way as GLP-1. because many of these patients need to be managed after they wean off of that first generation drug.

31:47So it's an exciting time. Obviously, a lot of activity in the space. You know, the estimates right now are it's a$30 billion market right now, going to almost 1.5 billion patients worldwide in obesity, going to$100 billion market size. So it's a very attractive area for investments. So going back to Sintas for just a moment, John, I mean, basically it mimics bariatric surgery. I mean, it's how does that actually work? Yeah, it's a coating that goes to the small intestine or duodenum where the food is digested and absorbed. And that really is also a trigger for these pathways, GLP-1 and others, that are causing obesity in patients.

32:32And this drug may act in a fashion, it's just entering clinical trials, so there's a long way to go to get to the point where it's being approved by the FDA. But the attractive features of it are that its delivery is elegant and the safety profile, at least early on in preclinical models, is promising. John, just to follow up on the GLP sort of taking up all the oxygen in the room, when you look at where you're standing on the FDA phase one, two and three, how much have GLPs really clogged up the system for other drugs that are coming through the pipeline? Has it extended that timeline that it's taking a drug to make it from phase one to phase three?

33:18No, it has not. I mean, the FDA has been highly efficient. If you look at the numbers of NDAs that are getting improved, they're on par with, if not more, than what's been seen in the recent past. So we're not seeing any delays. In fact, it's a very exciting time beyond cardiometabolic disease, as we see in various areas, such as oncology with new modalities like ABC, which has been a big area of investment by companies. You've seen a lot of takeouts with Pfizer buying C-Gen and AbbVie buying Immunogen. And you have a lot of activity right now in the neuro field. So I think that's going to be a promising area for investment where you'll see more breakthroughs.

33:57It was obviously exciting to see the FDA advisory panel unanimously vote to be favorable for the Alzheimer's drug for Lilly. So I think that's going to really open up a dawn of new activities around brain disease drugs, neurodegenerative diseases like Parkinson's and others. And we're seeing a lot of companies in that space that have recently come public that have products in the clinic. that I think we're going to be watching very closely. How has technology sped up the preclinical and also clinical stages, especially for the companies that you invest in in terms of costs and in terms of time?

34:34And I'm thinking of things like AI, which, of course, everybody's talking about, but also other technologies like brain organoids and the use of those in the study of neuroscience and neurological diseases. Well, we're really excited about some of the applications of AI and even quantum as you think about the convergence of that technology for simulation. So although it's early in the field, the applied nature of what can be done for simulation to speed up not only the discovery process, for example, molecular modeling and building the right molecule before it even reaches a patient, is obviously a way that we can be more effective from a cost management perspective.

35:14But even in clinical trial development, simulation studies and those kinds of things, we believe that AI will play a very important role in that feature. You know, really excited today with what happened here in Chicago with Tempest AI getting public with their debut priced at the high end of the range, seemed to trade up by the end of the day. That's good. I think anything that's working in their case, they're applying AI for diagnostic tools to make sure we're selecting the right patients to treat them with the right drugs and do that in a very rapid fashion. So that's going to be really cost effective on the back end.

35:51John, great to speak with you. We hope you come back soon. It's a pleasure. Thanks so much. So many fascinating things going on out there. He was really good. And, you know, look, I think it speaks to a couple of things. Tim talks about this. Competition is coming without question. On the flip side of the coin is in order to be competitive, a lot of these companies are going to have to buy things. And the structured therapeutics, I mean, I think Mizuho had a piece. They say they're a no-brainer takeout candidate. I agree. And the stock is actually pulled back from 56 down to 48. So that's really interesting here.

36:20And I think what you're seeing, too, in this space is GLP-1s are kind of the AI of the pharmaceutical space. And they really need a lot of those players in the game to become competitors in the space. And that's what you're seeing with Gilead is once you even hear, like, the inkling that they have something in the pipeline, It's shooting their stock up higher, and I think you're going to see a lot more of that needing those innovations to move forward. It is pretty amazing, though. I'm shocked that it's not clogging the pipes up for the FDA because Karen always talks about GLPs being the holy grail, and I think she's right.

36:48They're opening up neurological drugs, and John was talking about the heart and metabolic stuff. So I think it's top down. But to Guy's point, XBI, small cap biotech, is where you're going to see people start to gobble up companies. I think people have been ignoring that. It's interesting, though. XBI has had a little bit of a little bit of weakness over the last couple of days. And you're right, though. I mean, if you can pick out the right names, you can nail it. I just I think about this week and I think about Lily's announcement and Alzheimer's, too. And I just think it kind of reinforces who the big dog is.

37:22And I think investors know that. Coming up, pricing pain is hitting the fast food trade from Chipotle to Starbucks. Customers are taking to social media to complain inside the latest trends and how these companies are coping. More Fast Money in two.

37:39Welcome back to Fast Money. Restaurants under pressure as consumers take to social media to lament their frustrations over pricing and portions. But companies like Chipotle and McDonald's are pushing back on the viral video complaints. CNBC's Kate Rogers joins us now to dig into the details. Hey, Kate. Hey, Melissa. McDonald's making headlines in recent months. You may remember a location in Connecticut sold an$18 Big Mac meal and social media post regarding pricing really took off. U.S. President Joe Erlinger recently published an open letter saying the company has seen viral social posts that prices have been raised, quote, significantly beyond inflationary rates, which he says is inaccurate.

38:15Prices have increased, though, he admitted, between 20 and 40 percent for some items due to inflationary pressures. And then on TikTok, some consumers have made complaints about the serving sizes at Chipotle. CEO Brian Nichol telling our Jim Cramer that the company has, in fact, not changed its serving sizes, and the trend is a little rude to employees who want to serve customers what they want to eat. And when it comes to value, Chipotle's perception is actually holding up, according to data from TD Cowan's Andrew Charles, who recently wrote, Chipotle's value perceptions are outperforming the fast casual peer group at a widening clip at a rate of just under 50 % versus 42 % for peers' average of Shake Shack, Kava, and other names.

38:53And then at McDonald's, value perception is now slightly trailing its peer average at Taco Bell, Burger King, Wendy's, and more. Their rate is just over 46 % versus the average rate of 49%. I will note the perceptions of value at both McDonald's and Chipotle are not too far off from one another, but it really matters when you think about consumers taking to social media and how this stuff kind of spreads around. Melissa, back over to you. Kate, thanks. Kay Rogers. CMG, record high yesterday and today. It's incredible, isn't it? I mean, and valuation. This is one. This is the thing about Lilly, NVIDIA.

39:25They're all the same. Chipotle is the same thing. Nothing stops these names, and I don't think it's going to stop. I'll say this. I think Tim might agree. McDonald's at a market multiple trading basically against that October from last year low. I think it's actually pretty interesting here. I do. I think you can get a little bit lower, and whether that charts you start nibbling at 240 or not. The problem here for McDonald's is the segment they operate in. You go there for value. And so the$5 meal wars with Burger King. I mean, this stuff's heating up. I think it's going to get worse before it gets better.

39:55And if you look at the last couple numbers we've had, even on CPI, restaurants are the prices are going higher. And I think they're going to hit a wall. And I think it's an issue you want to get ahead of as an investor. Coming up, a monster call on micro strategy. Why Bernstein says this Bitcoin proxy play could nearly double. That's next.

40:18Welcome back to Fast Money. Bernstein now with a massive call on the Bitcoin trade. The firm calling for an 80 % surge in proxy play micro strategy, saying it deserves to trade at a 50 % premium to its Bitcoin NAV. Analysts calling for Bitcoin itself to hit 200 ,000 by the end of next year. That's about triple where it is now. I mean, what is micro strategy? A lot of people have done work on this. Premium. Exactly. Why not a discount? I'm confused. There's so many ways to invest in Bitcoin now. Yeah. Why do we need a proxy play to trade at a premium to Bitcoin? It's all fair. I think the bull argument is just the momentum, just the way this market is set up now.

40:58If Bitcoin goes higher, MSTR, regardless of whether or not it should, will go higher as well. I totally get that. And what is it? I think they now have 131 ,000 Bitcoin on their balance sheet. So, you know, you can say it's a software company. No, it's basically a Bitcoin holding company. And if Bitcoin goes higher, whether justified or not, MSTR will as well. Yeah, I think that's all valid points. It's up 137 percent year to date. But the problem is it bites both ways. So if it goes down, it's going to be the higher beta play as well to the downside. I just play it with iBit because I am a little bit cautious of these types of moves and I don't have the stomach for it.

41:37But if you're in crypto and you want that upside potential, then it probably makes sense to buy a little bit of this. I know it sounds like a Texas hedge where you're long the same thing, but that's the beta. Yeah, we we don't invest in Bitcoin. It's not something I recommend for our clients. But I would say if you're going to own it, I'd own it outright as opposed to like these background strategies of owning it. I do think this just goes to show how that risk on appetite is on right now. I mean, investors are looking for either cash at 5 % or something that's going to have really high returns.

42:07That's why you're seeing Bitcoin is doing well, along with MicroStrategy, which is going to trade in pairs with that. So, yes, could it do well? Maybe. It's not something I'm investing in, however. Bitcoin at$200 ,000. I mean, buy anything. Buy anything. I mean, come on. So, and maybe we get there. Maybe we aren't sure. Maybe Trump's picture's on it. I don't know. But I'd rather own Coinbase. Up next, Final Trade.

42:40Final trade, Tim. Happy Father's Day, Dad. And all dads, Boeing. Courtney. Walmart. This is our trade or fate that I can do again. Steve. Costco. Guy. Steve's birthday on Wednesday. BK's birthday today. Carter's birthday tomorrow. Wow. Valero. Happy birthday and happy Father's Day. Mad Money starts right now. All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.

43:26Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.

From the publisher

Apple and Netflix both having strong weeks as the stocks trade near record highs. What’s next for the names and what could their rise mean for the rest of the markets? Plus long-struggling Gilead getting a boost today on early results of its experimental obesity pill. Can it effectively compete with the likes of Eli Lilly and Novo Nordisk?

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Two Big Tech Moves That Caught Our Eye This Week, and Gilead Gets on the GLP-1 Train 6/14/24CNBC's "Fast Money" · 44 min
Listen in VO